Logo
x

Search

Subscribe Now

Mabwell

Mabwell’s Maiweijian (Biosimilar, Denosumab; 120mg) Receives the NMPA approval for Marketing Authorization in China

Mabwell’s Maiweijian (Biosimilar, Denosumab; 120mg) Receives the NMPA approval for Marketing Authorization in China

  • April 8, 2024
Mabwell Highlights Results from the P-III Study of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology

Mabwell Highlights Results from the P-III Study of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology

  • February 22, 2024
Mabwell Reports the US FDA’s IND Approval of 7MW3711 for the Treatment of Solid Tumors

Mabwell Reports the US FDA’s IND Approval of 7MW3711 for the Treatment of Solid Tumors

  • February 21, 2024
Mabwell Receives the NMPA’s IND Approval of 9MW2921 for the Treatment of Solid Tumor

Mabwell Receives the NMPA’s IND Approval of 9MW2921 for the Treatment of Solid Tumor

  • July 19, 2023
Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China

Mabwell’s Mailishu (biosimilar, denosumab) Receives the NMPA’s Approval for the Treatment of Osteoporosis in China

  • April 3, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.